Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to...

Full description

Bibliographic Details
Main Authors: Sandro Halwe, Alexandra Kupke, Kanika Vanshylla, Falk Liberta, Henning Gruell, Matthias Zehner, Cornelius Rohde, Verena Krähling, Michelle Gellhorn Serra, Christoph Kreer, Michael Klüver, Lucie Sauerhering, Jörg Schmidt, Zheng Cai, Fei Han, David Young, Guangwei Yang, Marek Widera, Manuel Koch, Anke Werner, Lennart Kämper, Nico Becker, Michael S. Marlow, Markus Eickmann, Sandra Ciesek, Felix Schiele, Florian Klein, Stephan Becker
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Viruses
Subjects:
SARS-CoV-2
monoclonal antibody
neutralizing antibody
virus
animal experiments
mice
Online Access:https://www.mdpi.com/1999-4915/13/8/1498

Internet

https://www.mdpi.com/1999-4915/13/8/1498

Similar Items